First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients
KM023-101
Phase 1 other active
Quick answer
First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients for Olmsted syndrome is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Olmsted syndrome
- Phase
- Phase 1
- Modality
- other
- Status
- active